Reference : Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Scientific journals : Article
Human health sciences : Hematology
Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Journal of Hematotherapy & Stem Cell Research
Mary Ann Liebert, Inc.
Yes (verified by ORBi)
[en] Hematologic Neoplasms/complications/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects/methods ; Humans ; Immunosuppression/adverse effects ; Transplantation Conditioning/adverse effects/methods ; Transplantation Immunology ; Transplantation, Homologous/adverse effects/methods
[en] Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for selected hematological malignancies. Its curative potential is largely mediated by an immune-mediated destruction of malignant cells by donor lymphocytes termed graft-versus-leukemia (GVL) effect. However, because of its toxicity, conventional allogeneic HSCT is restricted to younger and fitter patients. These observations led several groups to set up new (less toxic) transplant protocols (nonmyeloablative stem cell transplantation or NMSCT) based on a two-step approach: first, the use of immunosuppressive (but nonmyeloablative) preparative regimens providing sufficient immunosuppression to achieve engraftment of allogeneic hematopoietic stem cells and, in a second step, destruction of malignant cells by the GVL effect. Preliminary results showed that NMSCT were feasible with a relatively low transplant-related mortality (TRM), even in patients older than 65 years. In addition, strong antitumor responses were observed in several hematological malignancies as well as in some patients with renal cell carcinoma. After discussing the mechanisms and efficacy of the GVL effect as well as the rationale for NMSCT strategies, this article reviews the first results of ongoing clinical trials. Innovative modalities that may permit amplification of the GVL effect while minimizing the risk of GVHD are discussed. Because the benefits of NMSCT over alternative forms of treatment remain to be demonstrated, this strategy should be restricted to patients included in clinical trials.

File(s) associated to this reference

Fulltext file(s):

Open access
159.pdfPublisher postprint409.79 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.